XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE (EPS)
 6 Months Ended
Jun. 30, 2023
EARNINGS PER SHARE (EPS)  
EARNINGS PER SHARE (EPS)

10. EARNINGS PER SHARE (“EPS”)

Basic EPS is computed by dividing net income available to common stockholders by the weighted-average number of common shares outstanding. Diluted EPS is computed by dividing net income by the weighted-average number of common shares outstanding and dilutive potential common shares for the period. Potential common shares include the weighted-average dilutive effects of outstanding stock options and restricted stock awards using the treasury stock method.

The following table sets forth the number of weighted-average common shares outstanding used to compute basic and diluted EPS:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended

​

Six months ended

​

​

June 30,

​

July 1,

​

June 30,

​

July 1,

​

    

2023

    

2022

    

2023

    

2022

​

​

(in thousands, except per share amounts)

Net income (loss)

​

$

397

​

$

(4,326)

​

$

1,329

​

$

(8,099)

Weighted-average common shares outstanding

​

 

13,344

​

 

13,016

​

 

13,305

​

 

12,901

Effect of dilutive stock options and restricted stock awards

​

 

143

​

 

—

​

 

176

​

 

—

Weighted-average common shares outstanding-diluted

​

 

13,487

​

 

13,016

​

 

13,481

​

 

12,901

Earnings (Loss) per share:

​

​

​

​

​

​

​

​

​

​

​

​

Basic

​

$

0.03

​

$

(0.33)

​

$

0.10

​

$

(0.63)

Diluted

​

$

0.03

​

$

(0.33)

​

$

0.10

​

$

(0.63)

 

​

For the three and six months ended June 30, 2023, the Company excluded 451,000 and 433,000 common shares, respectively, subject to outstanding equity awards from the calculation of diluted shares because their impact would have been anti-dilutive. For the three and six months ended July 1, 2022, the Company reported a net loss, and accordingly, all outstanding equity awards have been excluded from such periods because including them would have been anti-dilutive.

​